Tacrolimus rescue therapy in patients with rejection and long-term dialysis after kidney transplantation

Clinical Nephrology

Volumn 49, Issue 1, 1998, Pages 24-27

  Witzke, O ^a   Becker, G ^a   Erhard, J ^a   Lutkes P ^a   Szabo, A ^a   Philipp, T ^a   Heemann, U ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Acute rejection; Kidney transplantation; Rescue therapy; Tacrolimus

Indexed keywords

CREATININE; CYCLOSPORIN; OKT 3; STEROID; TACROLIMUS;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MALE; PROGNOSIS; SURGICAL PATIENT; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MUROMONAB-CD3; RENAL DIALYSIS; TACROLIMUS;

EID: 0031973601     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Eberhard OK, Kliem V, Oldhafer K et al. 1996 How best to use tacrolimus (FK506) for treatment of steroid-and OKT3-resistant rejection after renal transplantation. Transplantation 15: 1345
2. Felldin M, Bäckmann L, Brattström C, Bentdal O, Nordal K, Claesson K, Persson NH 1995 Rescue therapy with tacrolimus (FK506) in renal transplant recipients - a multicenter analysis. Transplant Proc 27: 3425
3. Goldstein G, Schindler J, Tsai H et al. 1985 A randomised clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313: 337
4. Herget S, Heemann U, Friedrich J, Kribben A, Wagner K, Philipp Th 1996 Initial experience with tacrolimus rescue therapy in OKT3 resistant rejection. Clinical nephrology 45: 352
5. Jordan ML, Shapiro R, Vivas CA et al. 1994 FK506 "Rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 57: 860
6. Land W, Meßmer K 1996 The impact of ischemia/reperfusion injury on specific and nonspecific, early and late chronic events after organ transplantation. Transplantation Reviews 10: 108-127 and 236-253
7. Lim EC, Teraski PI 1991 Early graft function. In: P. Teraski, ed. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory
8. Lodge JPA, Pollard SG 1997 Neoral vs Sandimmun: Interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. Transplant Proc 29: 272
9. Ponticelli C, Rivolta E, Tarantino A et al. 1987 Rescue of severe steroid resistant rejection with OKT3-PAN. Transplant Proc 19: 1908
10. Ponticelli C, Minetti L, Di Palo FQ et al. 1988 The Milan clinical trial with cyclosporin in cadaveric renal transplantation. Transplantation 45: 908
11. Talbot D, Reddy KS, Watson D et al. 1995 Developing the ideal immunosuppressive protocol by internal audit. Transplant Int 8: 392
12. Tarantino A, Aroldi A, Stucchi L et al. 1991 A randomised prospective trial comparing cyclosporin monotherapy with triple drug therapy in renal transplantation. Transplantation 52: 53
13. Thistlethwaite JR, Haag BW, Gaber AO et al. 1987 The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporin. Transplant Proc 19: 1901
14. Troppmann C, Gillingham KJ, Benedetti E, Almond S, Gruessner RGW, Najarian JS, Matas AJ 1995 Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. Transplantation 59: 962
15. Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ 1996 One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. Transplantation 61: 1576